selpercatinib data present wclc show solid efficaci good
toler sale peg separ updat model
yesterday report data ph i/ii studi selpercatinib
patient ret fusion posit nsclc world confer lung
cancer wclc meet registr dataset compris patient ret
nsclc previous treat platinum-bas chemo patient confirm
orr unconfirm basi orr patient brain metastas
june data cut median dor month median
month although number view immatur event
occur patient treatment-na orr
unconfirm basi although unlik selpercatinib garner label
dataset term safeti patient discontinu therapi due treatment
relat toxic entir libretto studi attribut smatter
issu selpercatinib patient experienc treatment emerg hypertens
rate grade treat patient experienc treatment-rel hypertens
rate grade lilli target nda submiss earli eu
japan china nsclc patient diagnos year
ret fusion posit diseas distribut vari ethnic
patient today test ret fusion marker
orr consist previous report data wclc
updat monitor resist although patient relaps far
patient discontinu across entir studi popul increas
hypertens seen selpercatinib compar last updat notabl selpercatinib
ae tabl disclos inform regard cytopenia although confirm
none seen selpercatinib ae tabl disclos inform regard
consult report allerg reaction lilli previous state awar
case allerg reaction liver enzym elev revers manag
increas ep estim vs guidanc
thereaft ep clip year
ep forecast impli ep compound-annual-growth-rate unchang
industri averag oper margin forecast lower
rais
sale estim vs guidanc unchang
thereaft sale forecast lower modestli year sale
estim lower
sale compound-annual-growth-rate intact par industri averag sale
project jardianc cyramza emgal rais humulin
humalog lower
pleas see page report import disclosur
newer product portfolio good growth prospect tap tandem hand
late-stag agent pois launch next year give us confid
above-averag sale ep growth prospect estim ep compound-annual-growth-rate
compar industri averag dividend yield attract
verzenio breast cancer emgal
perform diabet busi
notabl trulic jardianc
data readout olumin atop
derm pegilodecakin pancreat
revenu growth leverag ep
growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
margin expans sooner greater
alimta declin rapidli
margin expans delay reduc
compani global biopharmaceut compani incorpor
indiana march lilli fulli spun anim health busi elanco lead
product area diabet metabol diseas oncolog among other
compani data cowen compani
compani data cowen compani
productstrul europ lc ex europ lc ex europ lc ex europ lc ex world-wide share europ lc ex europ lc ex europ lc ex europ lc ex world-wide share cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
healthfood end market sale euro end market sale world-wide share end market sale euro end market sale world-wide share cowen
compani data cowen compani
growth productstrul us share novo inject oral semaglutid risktrul europ lc ex fx -australia europetrul eu emerg marketstrul qweek dose type diabet rewind cv data file higher dose phase psoriasi market share europ lc ex fx taltz eu mod/sever psoriasi taltz axspa radiograph file non-radiograph basaglar/abasria settlement w/sni allow launch strong launchbasaglar/abasria europ lc ex fx basaglar/abasria market eubasaglar/abasria countri basaglar/abasria insulin glargin diabet lantu biosimilar expectedjardi us empa-reg cv outcom studi reflect labeljardi europ lc ex fx -australia europejardi eu empa-reg data file file jardiance/trajenta nda eujardi japanjardi emerg market approv chinajardi world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf type diabet file ckd heart failur pverzenio mbcverzenio europ lc ex fx verzenio mbcverzenio mbcverzenio inhib mbc adjuv bc prostat cancer cyramza expect despit competit pressur io target agentscyramza europ lc ex fx -australia europecyramza nsclc cyramza uptak gastriccyramza emerg marketscyramza ramucirumab approv gastric lung file lungolumi europ lc ex fx olumi inhib ra atop derm data posit sle alopecia areata w/incytradjenta market share patent expir europ lc ex fx -australia europetrajenta expir expir emerg marketstradjenta world-wide share inhibitor share gross profit bi reflect revenu cowen
compani data cowen compani
new drugsglucagon europ lc ex fx gucagon hypoglycemia intranas baqsimi approv launch spetmeb europ lc ex fx adcirca pulmonari arteri cgrp mab market episod chronic migrain cluster ha oral human ant-egfr approv squamou nsclc us activ ret-mut cancer phase ii via loxo acq close tx studi posit file oral altern deliveri consid via colucid diagnost tau imag agent phase data rapid act file dm develop phase ii data show strong efficaci ae concern phase ulcer coliti phase psoriasi phase crohn diseas phase pancreat cancer lung rcc melanoma solid tumor earlier deposit mab alzheim diseas phase iitgf beta phase sever pain cancer pain oa pain clbp phase safeti data rais question phase iibtk select non-coval btk inhibitor b-cell leukemias/lymphoma pi/ii initi aka insulin deliveri phase iibas phase dermat phase alzheim diseas phase iiforteo expir biosimilar launch new modal anticipatedforteo europ lc ex fx -australia europeforteo expir biosimilar launch anticipatedforteo patent expir emerg marketsforteo hormon osteoporosi two year durat treatmenterbitux sale full right close royalti europ lc ex fx -australia europeerbitux royalti report ou revenu key greater transpar drug solderbitux royalti royalti kgaa own asset due fulli paid licenseerbitux royalti cowen
compani data cowen compani
new drug continuedlartruvo soft tissu sarcoma announc studi fail confirm oslartruvo europ lc ex fx lartruvo phase ii pancreat cancer pdgf alpha mab withdrawn markettot growth new drug sale drugsalimta exp pedi extens vitamin supplement patent prevail appeal pto deni ipr vitamin supplement patent approv use keytruda nsclcalimta europ lc ex fx -australia europealimta exp vitamin supplement patent til eu upheld eu gener francealimta exp method-of-us patent emerg marketsalimta synthetas inhib mesothelioma nscl io/target agent impact nsclc usageciali launch day exclus end sell author genericciali europ lc ex fx -australia europeciali expir expir emerg marketsciali bphhumatrop europ lc ex fx -australia europehumatrop emerg marketshumatrop expir europ lc ex fx -australia canada europestrattera expir emerg marketsstrattera deficit hyperactivityzyprexa expir author gener sale book herezyprexa europ lc ex fx -australia europezyprexa expir expir gener launch emerg marketszyprexa cowen
compani data cowen compani
establish drug continuedeffi expir includ pedi exclus effient europ lc ex fx -australia europeeffi expir emerg marketseffi trilog medic mgd patient accoast pre-tx trigger drug elut stent miss endpointsprozac europ lc ex fx -australia europeprozac competitionprozac emerg marketsprozac expir multipl gener soldcymbalta europ lc ex fx -australia europecymbalta exclus expir gener launch mid patent expir emerg marketscymbalta pain gad fibromyalgia chronic paingemzar europ lc ex fx -australia europegemzar emerg marketsgemzar nsclc bladder breast ovarian gener evista expir multipl gener soldevista europ lc ex fx -australia europeevista expir expir emerg marketsevista breast cancer market eu pursu chf market foreign sale over-the-counter cowen
compani data cowen compani
oral cd outlicens dura antibiot focusinject divest china repres major salesoth inject antibiot market share sni biosimilar rcv approv discount version target accesshumalog europ lc ex fx -australia europehumalog biosimilar approv eu emerg marketshumalog act insulin patent expir europ lc ex fx -australia europehumulin emerg marketshumulin patent protectionoth productsinsulin patent expir intern product beirsdorf german drug manuf establish drug drug sale new product cowen
compani data cowen compani
compani data cowen compani
anim healthfood nv acquisit close addit jansen sales/yr lohmann sales/yr sales/yr total equiti model assum remaind retainedy/i industri averagey/i trajenta end market sale euro rate end market sale world-wide share inhibitor share gross profit bi reflect revenuejardi end market sale euro rate end market sale world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf piii type diabet file ckd heart failur piii cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
